On November 5, 2026, Precision BioSciences entered into an underwriting agreement for the issuance and sale of over 10 million shares of common stock and pre-funded warrants. The estimated net proceeds from the offering will be approximately $116.5 million. These funds will be used to further research and development efforts as well as for general corporate purposes. The offering is scheduled to close on November 6, 2026.
Who to call at Precision BioSciences, and when
A new round usually means Precision BioSciences is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Precision BioSciences raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Precision BioSciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Precision BioSciences. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Precision BioSciences
Location
302 EAST PETTIGREW STREET
Durham, North Carolina, United States
About
Precision is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, Precision’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Precision BioSciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
DurhamBiotechnologyHealth CareGeneticsTherapeutics